Can I buy Tarlatamab in the country-Imdelltra

Tarlatamab-Imdelltra is a new bispecific T-cell engager (BiTE) that mainly targets the tumor-associated antigen DLL3 and simultaneously activates the patient's own T cells, exerting an immune killing effect on malignant tumors with high expression of DLL3 such as small cell lung cancer (ES-SCLC). This innovative immunotherapy drug has shown good anti-tumor activity and controllable safety in clinical studies overseas, especially in the United States and Europe, and has entered Phase II and Phase III clinical trials.

However, in China, talatumumab has not yet received marketing approval from the National Medical Products Administration (NMPA), so the drug cannot currently be purchased through hospitals or regular pharmacies. This means that if domestic patients want to use talatumumab for treatment, they can only rely on participating in clinical trials, applying for international drug imports, or obtaining it through special international medical channels. However, these channels are usually restricted by strict enrollment conditions, legal supervision, and drug distribution specifications. Compared with other approved targeted or immunotherapy drugs in China, talatumumab is still in the early stage of introduction, which also reflects the gap in the development and approval of new bispecific antibodies for clinical application in China.

For clinicians, the emergence of talatumumab provides a new treatment strategy for patients with refractory small cell lung cancer. Its mechanism is different from traditional chemotherapy andPD-1/PD-L1 immune checkpoint inhibitors. It can directly guide T cells to recognize and kill DLL3-positive tumor cells, thereby improving treatment tolerance and anti-tumor response rate in some patients. As international clinical data continues to accumulate, talatumumab is expected to enter the market in China through clinical trials or special approval procedures in the future, providing patients with more immunotherapy options.

In short, talatumumab is not currently on the market in China, and patients cannot purchase and use it through conventional channels. They need to rely on international trials or special drug application channels to obtain it.

Reference materials:https://www.drugs.com/mtm/tarlatamab.html